

### Key Indices Update

Indices	Close	Change (%)
Nifty	22,819.60	2.09↓
Sensex	73,583.22	2.25↓
Midcap	54,097.80	2.23↓
Smallcap	15,620.00	1.74↓

### Trend Strength Indicator

Nifty 50 Stocks above 200 EMA	NSE Advance / Decline
14	503/2813

### Key Data

Data	Current	Previous
Dow Jones	44,932.8	46,147.2
U.S. Dollar Index	100.15	99.87
Brent Crude (USD/BBL)	116.30	106.82
US 10Y Bond Yield (%)	4.41	4.42
India 10Y Bond Yield (%)	6.93	6.87

### Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	52300.00	2.62↓
NIFTYAUTO	24334.15	2.89↓
NIFTYENERG	35227.95	0.92↓
NIFTYFINSR	26621.50	2.65↓
NIFTYFMCG	46381.40	1.91↓
NIFTYIT	29586.90	0.28↓
NIFTYMEDIA	1297.70	1.03↓
NIFTYMETAL	11166.45	1.55↓
NIFTYPHARM	22539.25	0.62↓
NIFTYREALT	669.60	3.25↓

## Fundamental

Refer Page 02

### Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
LUPIN	PHARMA	2,332	2,691	15.4%

\*CMP as on March 27, 2026

### Top News

- ✦ **Coal India (CIL), in a move aimed at improving the quality of its coking coal, is planning to set up eight new coking coal washeries at an estimated capital outlay of Rs 3,300 crore.** Expected to be operational by FY 2030 these would have a combined washing capacity of 21.5 million tonnes per year (MT/Y).
- ✦ **Prestige Group and Arihant Group, a reputed Chennai-based real estate company, have jointly acquired a prime 16.331 acre land parcel in Padi, Chennai.** The acquisition has been undertaken through Canopy Living LLP, a joint venture between Prestige Estates Projects and Arihant Foundations and Housing.

## Technical

Refer Page 03-04

- ✦ **Nifty extended their decline on Friday**, ending sharply lower and continuing the ongoing corrective phase amid weak global cues.
- ✦ On the technical front, **the Nifty continues to hover near crucial support levels**, indicating sustained pressure despite entering oversold territory.
- ✦ **Immediate support is placed around 22,500**, and a decisive break below this level could trigger further downside towards 22,000.
- ✦ **On the upside, 23,000 is likely to act as an immediate hurdle**, followed by a stronger resistance near the 23,500 zone in case of any recovery.
- ✦ Participants are advised to maintain a cautious approach, **avoid aggressive positioning, and focus on disciplined risk management** while adopting a selective, stock-specific trading strategy.
- ✦ **Stock of the day - LAURUSLABS**

## Fundamental

### Top News

01

**Coal India (CIL), in a move aimed at improving the quality of its coking coal, is planning to set up eight new coking coal washeries at an estimated capital outlay of Rs 3,300 crore.** Expected to be operational by FY 2030 these would have a combined washing capacity of 21.5 million tonnes per year (MT/Y).

02

**Prestige Group and Arihant Group, a reputed Chennai-based real estate company, have jointly acquired a prime 16.331 acre land parcel in Padi, Chennai.** The acquisition has been undertaken through Canopy Living LLP, a joint venture between Prestige Estates Projects and Arihant Foundations and Housing.

03

**PCBL Chemical's wholly owned subsidiary -- M/s PCBL (TN) has successfully commissioned additional brownfield capacity of 30,000 MT of carbon black at its plant in Tamil Nadu.** The commissioning of this expanded capacity will enhance the Company's production capabilities and contribute to its long-term growth plans.

04

**The Finance ministry has cut excise duty on petrol to Rs 3 a litre, from Rs 13 a litre earlier, while the levy on diesel has been slashed to nil from Rs 10 earlier,** offering relief to oil marketing companies (OMCs) from a sharp spike in global crude oil prices triggered by the ongoing geopolitical conflict in the West Asia. The duty cuts are effective immediately.

05

**Larsen & Toubro's (L&T) Buildings & Factories (B&F) business vertical has secured multiple orders across several states in India. In Gujarat, it has secured an order for the construction of a Float Glass Plant.** The scope includes design and construction of all civil, steel, mechanical, electrical & plumbing and associated external development.

### Stock for Investment

### Lupin Ltd.

<b>Stock Symbol</b>	<b>LUPIN</b>
<b>Sector</b>	<b>PHARMA</b>
<b>*CMP (₹)</b>	<b>2,332</b>
<b>^Target Price (₹)</b>	<b>2,691</b>
<b>Upside</b>	<b>15.4%</b>

- ✦ **Record Q3 Performance:** Lupin's revenue rose 24% and EBITDA 66% YoY, driven by strong operating leverage and an improved product mix.
- ✦ **US Business High:** North America sales surged 46% YoY, fueled by differentiated launches like Tolvaptan and healthy base portfolio volumes.
- ✦ **Global Momentum:** India's prescription business and emerging markets, specifically Brazil, grew strongly, diversifying Lupin's revenue beyond US generics.
- ✦ **Complex Growth:** A focus on biosimilars and injectables improves visibility, with projected FY25-27E earnings CAGR of 36.3%. Maintain Buy (TP ₹2,691).

\*CMP as on March 27, 2026

^Time horizon - upto 11 Months

# Technical

**Pressure resumed. Volatility to continue.**

## NIFTY

22819.60 ▼ 486.85 (2.09%)

S1

22500

S2

22000

R1

23200

R2

23500

Technical Chart : **Daily**



- ✦ **Nifty extended their decline on Friday**, ending sharply lower and continuing the ongoing corrective phase amid weak global cues.
- ✦ **Immediate support is placed around 22,500**, and a decisive break below this level could trigger further downside towards 22,000.
- ✦ **On the upside, 23,000 is likely to act as an immediate hurdle**, followed by a stronger resistance near the 23,500 zone in case of any recovery.
- ✦ Participants are advised to maintain a cautious approach, **avoid aggressive positioning, and focus on disciplined risk management** while adopting a selective, stock-specific trading strategy.

## BANKNIFTY

52274.60 ▼ 1433.50 (2.67%)

S1

51500

S2

51000

R1

53500

R2

54300

Technical Chart : **Weekly**




- ✦ **The banking index declined on Friday**, reversing gains recorded over the previous two sessions and aligning with earlier signs of weakness.
- ✦ **It opened with a downward gap and remained under sustained selling pressure** throughout the session, trading significantly below its short-term moving averages.
- ✦ **Broad-based liquidation was observed across constituents**, led by Bank of Baroda and Punjab National Bank.
- ✦ Immediate **resistance is seen near 54,300**, with strong **support established around 51,000**.

Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
<b>LAURUSLABS</b>	<b>BUY</b>	1008.80	1005-1010	985	1055

Technical Chart : Daily



- ✦ **LAURUSLABS is exhibiting an improving bullish structure post-correction**, with price reclaiming and sustaining above its short-term moving average, indicating renewed buying interest.
- ✦ The formation of **higher lows within a symmetrical triangle suggests potential bullish continuation** and accumulation.
- ✦ **Momentum is turning constructive**, while volume expansion on advances reinforces strengthening bullish sentiment.
- ✦ **Market participants may consider initiating long positions** within the prevailing consolidation range.

Momentum Stocks Midcap	Name	Price	Price %
	GRAPHITE	635.90	6.74 ↗
	KARURVYSYA	297.65	4.51 ↗
	BRIGADE	695.30	3.64 ↗
	GREENPANEL	170.26	6.48 ↘
	MAHLIFE	310.90	7.83 ↘

Name	Price	Price %	Range Breakout/ Breakdown
UPL	596.20	4.65 ↘	
TMPV	303.20	4.64 ↘	
BANKBARODA	260.45	4.49 ↘	
PNB	105.16	4.46 ↘	
UNITDSPR	1253.30	4.44 ↘	

Top 5 F&O Gainers ↗	Name	Price	Price %
	OFSS	6945.50	5.25 ↗
	ONGC	282.55	4.57 ↗
	LICHSGFIN	505.90	1.93 ↗
	OIL	478.45	1.50 ↗
	WIPRO	191.75	1.43 ↗

Name	Price	Price %	Top 5 F&O Losers ↘
PGEL	488.20	5.61 ↘	
LODHA	694.80	5.32 ↘	
SHRIRAMFIN	905.30	5.30 ↘	
PAYTM	1012.70	4.99 ↘	
UPL	596.20	4.65 ↘	

Bullish Charts	Name	Price	Price %
	AUROPHARMA	1314.00	0.47 ↗
	MANKIND	2035.30	0.56 ↗
	NATIONALUM	371.10	1.03 ↗
	PPLPHARMA	142.21	0.81 ↗
	SAMMAANCAP	148.33	0.99 ↗

Name	Price	Price %	Bearish Charts
ASHOKLEY	163.02	4.64 ↘	
HUDCO	167.75	4.61 ↘	
NBCC	80.61	4.63 ↘	
RELIANCE	1348.20	4.59 ↘	
TMPV	303.20	4.64 ↘	

## Research Team

Name	Email ID
<i>Ajit Mishra</i>	<a href="mailto:ajit.mishra@religare.com">ajit.mishra@religare.com</a>
<i>Abhijeet Banerjee</i>	<a href="mailto:abhijeet.banerjee@religare.com">abhijeet.banerjee@religare.com</a>
<i>Gaurav Sharma</i>	<a href="mailto:gauravsharma2@religare.com">gauravsharma2@religare.com</a>
<i>Ashwani Harit</i>	<a href="mailto:ashwani.harit@religare.com">ashwani.harit@religare.com</a>
<i>Divya Parmar</i>	<a href="mailto:divya.parmar@religare.com">divya.parmar@religare.com</a>
<i>Rajan Gupta</i>	<a href="mailto:rajan.gupta1@religare.com">rajan.gupta1@religare.com</a>
<i>Vivek Chandra</i>	<a href="mailto:vivek.chandra@religare.com">vivek.chandra@religare.com</a>
<i>Himanshu Gupta</i>	<a href="mailto:himanshu.gupta1@religare.com">himanshu.gupta1@religare.com</a>

## Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

**Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:**

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? <b>[If answer is yes, nature of interest is given below this table]</b>		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes: ..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

*No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results*

